MUC1 and non-small cell lung carcinoma: The majority of these approaches have their basis in targeting specific tumor associated antigens (TAAs) such as epidermal growth factor receptor (EGFR), over-expressed in over half of lung cancer cases, which has been targeted using Cimavax-EGF, an immunogenic recombinant protein vaccine or Mucin-1 (MUC1), also over-expressed in non-small cell lung cancer using Simuvax, a liposomally delivered MUCI peptide.